Blockchain Registration Transaction Record

Nutriband Files Patent to Protect AVERSA Abuse-Deterrent Tech

Nutriband files patent for AVERSA™ abuse-deterrent tech, potentially extending protection to 2046. A significant step in combating opioid abuse and enhancing investor value.

This patent filing could significantly extend market exclusivity for Nutriband’s AVERSA™ technology, potentially through 2046, providing a competitive edge in the fight against opioid abuse. By enhancing intellectual property protection, Nutriband may attract further investment and partnerships, accelerating the development of abuse-deterrent transdermal products that address a critical public health crisis. For investors, this strengthens the company’s long-term value proposition; for patients and healthcare providers, it promises safer pain management options.